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Abstract
Background: In spite of our extensive knowledge of the more than 20 proteins associated with different amyloid diseases,
we do not know how amyloid toxicity occurs or how to block its action. Recent contradictory reports suggest that the fibrils
and/or the oligomer precursors cause toxicity. An estimate of their temporal concentration may broaden understanding of
the amyloid aggregation process.
Methodology/Principal Findings: Assuming that conversion of folded protein to fibril is initiated by a nucleation event, we
back-calculate the distribution of nuclei concentration. The temporal in vitro concentration of nuclei for the model
hormone, recombinant human insulin, is estimated to be in the picomolar range. This is a conservative estimate since the
back-calculation method is likely to overestimate the nuclei concentration because it does not take into consideration fibril
fragmentation, which would lower the amount of nuclei
Conclusions: Because of their propensity to form aggregates (non-ordered) and fibrils (ordered), this very low concentration
could explain the difficulty in isolating and blocking oligomers or nuclei toxicity and the long onset time for amyloid
diseases.
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Introduction
Even though the ancient Greek and Roman philosophers
associated old age with increasing dementia, it was not until 1901
that German psychiatrist Alois Alzheimer connected amyloid fibrils
withdementia [1]. Since then, considerable progress has been made
in characterizing amyloid diseases [2–4]. Together with b-amyloid
peptides [5,6], many other proteins are part of the amyloid family:
Islet amyloid polypeptide (type 2 diabetes mellitus) [7], a-synuclein
(Parkinson’s disease) [6], prions (transmissible spongiform enceph-
alopathy) [8] and huntingtin (Huntington’s disease) [9]. However,
the connection between amyloidosis and disease is still unclear.
Recently, oligomeric precursors of fibrillation have been proposed
as possible toxic agents responsible for disease [10,11]. Detailed
analysis of these species, however, is still missing, mainly because of
the inherent experimental challenge associated with isolation and
structural characterization of individual components in a dynamic
multi-component equilibrium. In this study, recombinant human
insulin as a model amyloid protein was used, whose fibrillation
mechanism is well characterized [12–15]. As early as 1957, Waugh
proposed that a nearly simultaneous interaction of three to four
insulin monomers forms a nucleus [16]. Later many other groups
used differenttechniquestoidentifyoligomeric species:Electrospray
mass-spectroscopy (ES MS) [17], dynamic light scattering (DLS)
[18,19], atomic force microscopy (AFM) [20], synchrotron small
angle X-ray scattering (SAXS) [21] and small angle neutron
scattering (SANS) [22]. Among these, SAXS and SANS have
advantages for obtaining structural information and allowed
Vestergaard et al. and Nayak et al. to show the presence of
oligomers as building blocks during insulin fibrillation [21,22]. To
overcome the different limitations of these techniques (e.g. the need
for high sample concentration, the difficulty in characterizing
mixtures, the requirement that samples must be stable during the
time of the analysis and not be degraded by unwanted temperature
increases), researchers have recently developed fluorescent methods
[23] and used monoclonal antibodies [24] to capture the
intermediate oligomeric species. However, no general consensus
has been reached. Here, we offer a conservative theoretical estimate
of nuclei concentrations using a ‘‘reverse calculation’’ in which fibril
lengths are used to back-calculate the concentration of nuclei
originally present during aggregation. The method is conservative
because could overestimate the nuclei concentration, which would
be lower (roughly 1 order of magnitude) when fibril breakage is
considered as in some recent amyloid models [25–27]. No one, to
our knowledge, has used this relatively simple method previously.
Results
Observations and assumptions
Previously we have studied insulin fibrillation, a process
characterized by the following multiple stages: (i) a lag phase in
which the nucleation process proceeds and no detectable fibrils are
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lengths of fibrils are formed over a time period often shorter than
the lag phase, and (iii) a saturation phase when elongation is
terminated as most soluble protein is converted into fibrils [28].
Here, we question whether the end point of the process could
provide information on the earlier stages, and specifically the
nuclei concentration. We have observed the following: (i) Samples
taken at different times along the oligomer reaction path (lag
phase) exhibit linearly changing behaviour, supporting the idea of
having in solution transient reactive species, which are the
prerequisite for forming structurally rearranged intermediates
and then fibrils; (ii) When aggregated species (oligomers/fibrils)
reach a certain size they do not interact with each other within the
time constraints of the measurement, probably because of
significantly slower diffusion rates [28]. Instead, they react
vigorously with free monomers, dimers or other small oligomers,
in an elongation process that is many orders of magnitude faster
than the nucleation process [29]. Defining the nucleus as the
smallest oligomeric entity, on which fibril-like structures are built,
we then assume that each fibril is generated by one nucleus and
the number of nuclei corresponds to the number of the formed
fibrils. Equivalent definitions of the nucleus are present in the
literature: (i) the least thermodynamically stable species in solution,
which is the oligomer of minimal size capable of initiating further
growth [30] and (ii) the aggregate size after which the association
rate exceeds the dissociation rate for the first time [31]. All these
assumptions are independent of the particular size of the nucleus,
which is also matter of debate since researchers have proposed
critical sizes up to 40 monomers [32].
Total number of nuclei
The challenge then is to estimate the number and length of fibrils
in solution. To do this, we first collected fibrils that were produced
with our standard protocol for insulin fibrillation, using 2 mg/ml
insulin solution, acidic buffer (pH 1.6) and high temperature
(6562uC). Samples were incubated for at least 5 hours, in order to
reach the saturation phase. Then AFM was used to characterize the
fibril length distribution. The data was fitted with 60 different
distribution models [33], and the Weibull model with the best
goodness-of-fit characteristics (i.e. Kolmogorov-Smirnov, Anderson-
Darling and Chi-Squared) was chosen. Assuming the measured
system (Figure 1) represents the whole sample, and knowing what
fraction of the system has been measured, this allows us to estimate
the total number of fibrils, and consequently the number of nuclei,
assuming each fibril was generated by a single nucleus. Using
electron microscopy, X-ray fibril diffraction, and biochemical
studies, Ivanova et al. [34] proposed a model for fibrils of human
insulin comprising two molecules per 4.7 A ˚ layer of the fibril. This
distance was suggested as one of the most conserved features of all
amyloid fibril structures since 1968 [35]. This information can be
converted into monomer density per unit fibril length, d=2/
0.47=4.26 monomer/nm. Using this information and the fibril
length distribution (Figure 1), one can estimate Nu,m, the number of
monomeric units involved in the analyzed system. From Eq. (1)
(Figure 2), Nu,m=2.33*10
6 monomers, when considering data
up to a cumulative function of PL  
i
  
~
Ð L 
i
0 fL ðÞ dL~0:998 for
Li
*=3566 nm, where f(L) is the probability density function. This
number of monomers is only a fraction, x, of all the monomers in the
whole system. For an initial 2 mg/ml of insulin, or 0.000344 M
(M.W. 5808 Da), the total number of monomers present in solution
was Nu,t=0.00034*(6.023*10
23)/1000=2.074*10
17 monomers/ml.
For 1 ml, from Eq. (2) (Figure 2) the fraction measured in the
sampleshowninFigure1,x=2.33*10
6/2.074*10
17=1.123*10
211.
With this fraction of the whole sample, one can estimate the total
number of fibrils, Nf,t, present in the whole sample and therefore the
number of nuclei, Nn,t, from Eqs. (3) & (4) (Figure 2). From
Figure 1, the total number of measured fibrils (up to 99.8% of the
area under the curve) of different lengths in the sample is obtained
fromthe Weibulldistribution,Nf,m=492.Hence,the totalnumberof
fibrils formed in the whole sample was Nf,t=Nn,t=492/x=492/
1.123*10
211=4.38*10
13. In terms of concentration, we obtain the
total nucleus concentration, cn,t=4.38*10
13/(6.023*10
23)/0.001=
7.27*10
28 M=73 nM over the whole period.
Time-dependent concentration of nuclei
Why do fibrils have different lengths? To answer this
question, we designed a set of seeding experiments, where we
generated fibrils with different lengths and followed their
elongation process. Since our results show that different length
fibrils have similar elongation rates (Figure 3), it seems
reasonable to hypothesize that fibril length is related to nucleus
f o r m a t i o n .F o re x a m p l e ,a s s u m i n gt h a tf i b r i l sw i t hal e n g t ho f
1500 nm were generated by nuclei formed in solution at time t
*,
then (i) fibrils with L.1500 nm were generated by nuclei
formed at t,t
*, giving them the time to grow longer than
1500 nm; while (ii) fibrils with L,1500 nm were generated by
nuclei formed at t.t
*, i.e. these nuclei were not present in
solution at t
*. Hence, the fibrils length scale (Figure 1,
horizontal-axis) is equivalent to a time scale. Reading the
probability density function profile in Figure 1 from right to
left, the amount of nuclei at the beginning of the nucleation
process was very small (long fibrils), it increased during the lag
phase until it reached a maximum (at L,900 nm), and finally it
decreased (short fibrils), most likely because of the presence of
mature fibrils formed during earlier stages for which the
e l o n g a t i o np r o c e s sw a sm u c hf a s t e rt h a nt h er a t eo fn u c l e i
formation. This trend is comparable to the results by
Vestergaard et al. [21], who found a helical insulin oligomeric
species accumulating and reaching a concentration maximum
during the elongation phase. Our assumption suggests that all
the nuclei calculated above, Nn,t, are not present in solution at
the same time, but represent an integral of all nuclei during the
experiment. Hence, we refine our analysis (above), keeping in
mind that the fibril count, Nfi or vertical-axis (Figure 1), is
related to nuclei concentration and the length scale, Li or
horizontal-axis, to the time scale. The results, however, depend
on the choice of a bin size, which determines the amount
(nuclei concentration) of single elements, i.e. nuclei formed at
different time points during the fibrillation process. In
agreement with the model for fibrils of human insulin proposed
b yI v a n o v ae ta l .[ 3 4 ] ,w i t h two molecules per 4.7 A ˚ length of
the fibril, the smallest bin size possible is the 2 monomers/bin,
which corresponds to a 0.47 nm/bin. Using this bin size, we
estimated a maximum concentration of 22 pM for the defined
nuclei. Obviously, the choice of the bin size is arbitrary and
ultimately depends on the elongation rate of fibrils. Since we
have shown that elongation rates for the different lengths of
fibrils are very similar (Figure 3), it is reasonable to assume 2
monomers/bin. However we have investigated the possibility
that fibrils, even of the same length, had different elongation
rates. As a consequence, nuclei present at the same time will
generate fibrils with different lengths, and this difference would
determine the correct bin size to choose. We have considered
larger bin sizes, as multiples of the previous bin size, up to 20
monomers/bin (equivalent to 4.7 nm/bin and to a
116.16 kDa/bin), whose maximum concentration is 10 times
larger than with 2 monomers/bin, but still in the pM range
(Figure 4).
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We have estimated a maximum concentration of insulin nuclei
in the pM range. This result can be extended to oligomeric species
larger or smaller than the nucleus. For the smaller oligomeric
species that can self-interact and generate nuclei, their concentra-
tion has to be higher than that predicted here. However, their
number (concentration) is likely to be the same order of magnitude
as that of the nuclei. This is supported by recent results from our
group, where oligomeric entities appear to be present below the
5 pM detection limit for the electrospray differential mobility
analysis method (ES-DMA) [36]. Moreover, most of the protein
maintains its original conformational structure and adds directly to
the nuclei and fibrils in the elongation process, without passing
through a series of intermediate to large oligomers. Hence, even
though the formation of nuclei takes time (lag-phase) and there are
very few nuclei in solution (pM range), the small native protein
with its large value of diffusivity is quickly consumed as a simple
building block. This is also confirmed by Sorci et al. [28].
Supporting information and validation
Unfortunately data on time-dependent insulin nuclei concentra-
tion are not available to date, in order to validate our approach
through a direct comparison between prediction and experimental
data. Also experimental conditions and the definition of a nucleus
change from author to author. Some considerations, however, can
be still made. Nettleton and co-authors were able to identify the
presence of oligomeric species using ES MS [17]. Before heating the
sample, mass spectra showed predominantly monomeric and
dimeric insulin with lower proportions of tetramer, pentamer and
hexamer. After heating for 30 min at 70uC, the intensity of the
hexamer andtetramer charge states werereducedrelative to those of
the pentamer. After 1.5 h, the presence of higher oligomers was
significantly reduced and after 2 h monomeric insulin was the only
species that could be observed in the mass spectrum. As the authors
pointed out, the proportion of aggregating species detected by mass
spectrometry was relatively low in comparison with monomeric
species, with the intensity associated with the 12-mer generally being
less than 0.1% of the signal for the monomer. These results cannot
be used to validate our estimates here, but the lack of higher
molecular weight oligomers support the idea that the concentration
is probably below the detection limit of the instrument. As
mentioned above, we obtained similar results using ES-DMA [36].
Using DLS both Grudzielanek et al. [18] and Ahmad et al. [19]
showed that the oligomeric peak, which appears as monomeric/
dimeric insulin, decreases and is quite broad, indicating the presence
of a heterogeneous mixture of oligomers. However a distribution of
the individual species is again not provided. Similar consideration is
indicated from SAXS [21] and SANS [22] data. Podesta ´e ta l .
calculated oligomers distributions for insulin aggregation combining
time-resolved AFM and static light scattering [20], resulting in a
steady-state distribution with an exponential tail until the formation
of amyloid fibrils. The median aggregation size at different time
points was 5.9, 4.9 and 6.7 nm, but the authors also pointed out that
small species were filtered out by the edge-detection-algorithm used,
which would decrease the medium aggregation size and the
percentage of larger aggregates. Using a different technique, single
molecule fluorescence, Orte et al. showed similar oligomer size
distribution during aggregation of the SH3 domain of PI3 kinase
[32]. The distribution of sizes for detected oligomers in solution was
Figure 1. Fibril length distribution. The histogram of frequency versus fibril length summarizes AFM data for 495 insulin fibrils in 36.6 nm/bin for
a total of 100 bins. The parameters of this distribution were estimated using distribution-fitting software, EasyFit (MathWave Technologies). The
software fitted the data using 60 different distributions and ranked the results based on three different goodness-of-fit tests. The histogram shows
the best fit (Kolmogorov-Smirnov statistic, D=0.0187, Anderson-Darling, A
2=0.323, and Chi-Squared, x
2=5.113) using the Weibull distribution (line).
The probability density function is fL i ðÞ ~
a
b
Li
b
   a{1
exp {
Li
b
   a   
with values of the parameters: a=1.7409 and b=1248.5. (A) Example of a 2D
AFM image of insulin fibrils, with measurements: A free-hand curve was drawn on the fibril and two cursors placed at each fibril end. Measurements
are in nm. (B) Example of a 3D image, which assisted in detecting individual fibrils.
doi:10.1371/journal.pone.0020072.g001
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average size of 30 monomers. These data qualitatively support our
approach, since our fibril distributions suggest a similar trend for the
oligomeric species. On the other hand, they cannot be directly used
to validate our estimates, since (i) they are distributions of oligomers
of different sizes and not of nuclei (1 defined size) versus time, and (ii)
they comprise frequency data without a mass balance to translate
into concentration data as we have done.
A conservative estimate
As in this work, the amyloid fibrillation process has been
traditionally analyzed according to the classic nucleation-depen-
dent polymerization model known as the ‘‘Oosawa’s model’’ [37].
However, other and more complicated mechanisms have been
proposed: Colloidal coagulation, downhill polymerization, and
secondary nucleation (branching, fragmentation and heteroge-
neous nucleation) [31]. In particular, especially in the last decade,
some researchers have proposed that the fibrillation kinetics is
controlled in large part by the rate of fibril fragmentation, where
fibrils break during the elongation phase and represent an
additional source of new filaments in solution [25–27]. In this
fragmentation model, multiple fibrils are generated by a single
nucleus, while our more simplified theory proposes a one-to-one
correspondence between fibrils and nuclei. According to our
estimate, the time-dependent concentration of nuclei reaches a
maximum value no larger than 250 pM and as small as 22 pM, or
smaller if fibril breakage contributes significantly to the fibril
formation mechanism. For example, consider the recent work on
modeling insulin fibrillation by Knowles and co-authors, and
the rate of multiplication of the filament population, k~ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2:mtot:kz:k{
p
, where mtot is the total monomer concentration,
mtotk+ the elongation rate and k2 the fragmentation rate [27].
In that work, insulin fibrils were formed at 60uCa n dp H 2 . 0 ,
close to our experimental conditions. Using the parameters k+=
2.9*10
4 M
21 s
21 and k2=2.1*10
29 s
21 (estimated by Knowles and
co-authors) and mtot=2/5808=3.44*10
24 M=344 mM( s i n c ew e
used 2 mg/ml insulin in solution), one can estimate a rate of
multiplication of the filament population k=0.000205 s
21.T h u s ,i t
takes 1/k=4 8 8 3s=1 . 3 5h t o m u l t i p l y t h e p o p u l a t i o n o f t h e
filaments. Since our fibrillation process is completed in about 5–
6 hours, the fibril population can multiply 4 times at most and 1
nucleus will generate 2
4=16 fibrils, decreasing our original estimate
by about 1 order of magnitude only. In other words, our picomolar
concentration predictions for the nuclei are conservative compared
with more complicated models that account for fragmentation. Also,
all secondary mechanisms are strongly dependent on stirring and
fibrils present in the solution, neither of which was involved in
generating the fibrils used in our calculation: Samples were not
agitated during fibrillation and seeds were not added to the fresh
insulin solution at the beginning of the experiment.
Limitations
We suggest that the reason nuclei are still structurally
uncharacterized, is not only because they belong to a very dynamic
multi-component system, but also because of low experimental
resolution. This analysis is based on the nucleation model, the
structural design of which is unknown [21,22]. We also do not know
how such nuclei convert to fibrils, which at least for insulin do not
appear to mostly grow symmetrically from each end [38]. Clearly
circular structures like those proposed by Quist et al. [39] may have
difficulty elongating, while asymmetric structures may elongate
more easily [38]. Recently, Meng et al. [40] have demonstrated that
1.0 mm diameter hard spheres with short-range attraction in water
formed asymmetric clusters rather than symmetric ones. For 6
spheres (two groups independently suggest that nuclei comprise 6
monomers or 3 dimers) [21,22], they observed two final structures
both with 12 contacts and similar potential energy; one asymmetric
(poly-tetrahedron) structure and one symmetric (octahedron)
structure at 96% and 4% cluster probability, respectively. It seems
that the asymmetric structures are likely to form fibrils than the
symmetric ones (see the Vestergaard et al. [21] paper and
supplementary movie demonstration fibril growth with asymmetric
hexamer nuclei). The approach presented here is not exhaustive
and there is room for refinement (e.g. knowing precise elongation
rates of fibrils and the exact bin size for the statistical analysis,
including the contribution of the secondary fragmentation mech-
anism in estimating the total amount of nuclei). The results do not
answer questions like ‘‘which is the correct nucleation mechanism?’’
or ‘‘which entity (the oligomer or the fibril) is the toxic one?’’, but
Figure 2. Equations and variables. Set of equations used to
estimate the total number of insulin nuclei, Nn,t, from the available fibril
length distribution. The number of measured fibrils per i-th bin, Nfi, Eqs.
(1) & (3), were calculated using the Weibull distribution (Figure 1).
From the definition of the nucleus, the total number of fibrils, Nf,t,i s
equivalent to the total number of nuclei, Nn,t, Eq. (4). A description and
the units are provided for each variable.
doi:10.1371/journal.pone.0020072.g002
Evaluating Nuclei Concentration
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20072aim to help researches to better target these oligomeric entities, and
point out the need for new analytical techniques to investigate them.
In this direction Lindgren and Hammarstro ¨m describe fluorescent
probesasa new tool forsensitivedetectioninreal-timeof oligomeric
precursor [23]. This would also provide experimental data to check
the validity of our approach and estimates.
Conclusion
A conservative theoretical ‘‘reverse’’ calculation to estimate
nuclei concentration, during the lag-phase of insulin aggregation,
is proposed based on experimental results (AFM fibrils distribution
and seeding experiments to investigate elongation rates of fibrils
with different lengths) and a structural fibril model proposed in the
literature [34]. For insulin nuclei, defined here as the precursor to
the initiation of fibril formation, they are present in the pM
concentration range. Even lower concentration would occur when
fibril breakage is considered. The approach is general and could
be extended to other amyloid systems. Our calculation is the first
attempt, to our knowledge, to quantify the nuclei concentration
and may broaden understanding of amyloids aggregation.
Materials and Methods
Reagents
Human recombinant insulin was provided by Novo Nordisk A/
S, Denmark. NaCl and HCl were certified ACS reagent grade
(Fisher Scientific, Pittsburgh, PA and Sigma-Aldrich, St. Louis,
MO, respectively). Buffer solutions were filtered prior to use
through a 0.22 mm poly(ether sulfone) membrane filter (Millipore
Corp., Bedford, MA).
The standard protocol for insulin fibrillation
Each kinetic experiment was performed at 6562uC with fresh
2 mg/ml insulin solution in 100 mM NaCl and 25 mM HCl
(pH 1.6), prepared immediately prior to use. Fibrils production
was followed by monitoring the increase in suspended matter via
absorbance at 600 nm (A600). As a complementary measurement,
fibrils were removed by centrifugation (12,000 rpm, 15 min) and
the supernatants were assayed at A280 to measure insulin depletion.
Complete description of the protocol and of the resulting
sigmoidal curve is provided in previous work [28]. The fibrils
used here were collected from insulin samples incubated at
6562uC for at least 5 hours, to assure the asymptotic phase was
reached, and without centrifugation, to avoid breakage of the
Figure 3. Elongation rate of fibrils with different length. A fresh 2 mg/ml insulin solution was seeded using fibrils with different length: 1L
(light blue square), 1.5L (dark blue square), 2L (pink triangular), 2.5L (dark purple triangular), 3L (light green circle), 3.5L (dark green circle), 4L (yellow
diamond), 4.5L (red diamond), 5L (orange square). The number of fibrils added as seeds was kept constant in all runs. (A) The elongation process was
followed with absorbance at 600 nm (A600) and fitted with an empirical model (lines) already introduced in the literature [15,28]. The equation is
reported as an insert: A600,ini is the A600 at the beginning of the experiment, A600,asym is the asymptotic A600 at the end of the fibrillation process, t is
the time, t50 marks the middle of the fibrillation process and t is representative of the sigmoid curve slope during the fibril growth phase. (B) After
normalization of the data, using the new coordinates X9 and Y9 reported as an insert, all runs overlap and can be fitted with a universal sigmoidal
curve derived from the same empirical model (line): Parallel slopes (kapp=1/t=0.86 min
21, with an R
2=0.87 from a linear fitting) is an indication of
similar elongation rates, independent from the length of the fibrils used.
doi:10.1371/journal.pone.0020072.g003
Figure 4. Nuclei concentration. Calculated profiles of nuclei
concentrations (pM) versus length (nm), or equivalently time scale, as
a function of the bin size. 2 monomers/bin corresponds to 0.47 nm/bin,
while 20 monomers/bin corresponds to 4.7 nm/bin.
doi:10.1371/journal.pone.0020072.g004
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spectrophotometer (Hitachi U-2000, Hitachi High Technologies
America, Inc., San Jose, CA).
Seeding experiment
This set of experiments was designed to generate, in a controlled
way, different length fibrils and then study their elongation
mechanism. The protocol comprises three steps. Step 1 –
Generating fibrils: In order to generate fibrils with different
length, we first collected ‘‘1L-fibrils’’ at the end of a standard
kinetic experiment. These fibrils are also known in terms of mass
(e.g. 2 mg in a 1 ml solution) and are characterized by their length
at the maximum frequency. Step 2 – Elongating fibrils: Longer
fibrils were then generated adding amounts of fresh insulin to a
known amount of ‘‘1L-fibrils’’ (e.g. for ‘‘2L-fibrils’’: 2 mg of ‘‘1L-
fibrils’’ +2 mg of fresh insulin) and allowing the fibrils to elongate.
The assumption is that the system did not form a significant
amount of new nuclei, but just elongated the pre-existing ‘‘1L-
fibrils’’. This assumption is supported by the different time-scales
of the two phenomena: It takes hours to form nuclei and then
fibrils, while the elongation process is completed in minutes. Step 3
– Seeding fibrils: Finally fibrils with different length were added as
seeds to a fresh 2 mg/ml insulin solution. The number of fibrils
added as seeds was kept constant in all runs. The elongation
process was followed with absorbance at 600 nm (A600).
Atomic force microscopy
Images of insulin fibrils (inserts) were obtained with an AFM
(MFP-3D, Asylum Research, Santa Barbara, CA) and standard Si
cantilevers (AC240TS, Olympus America Inc., Center Valley,
PA). Samples were diluted 1:100 with deionized water and then an
aliquot of 20 mL was placed on a mica surface for adsorption for
5 min. Non adsorbed protein was washed away with deionized
water. Three dimensional measurements were collected in air
using the tapping mode technique of AFM. 2D images were
analyzed with Igor Pro software (Wavemetrics Inc., Portland, OR)
for estimates of fibril length.
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